Elanco Animal Health Incorporated (NYSE:ELAN – Get Rating) has been given an average recommendation of “Buy” by the ten brokerages that are presently covering the firm, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $38.00.
Several research analysts have recently issued reports on ELAN shares. Barclays upped their price objective on Elanco Animal Health from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Monday, February 28th. Zacks Investment Research upgraded shares of Elanco Animal Health from a “sell” rating to a “hold” rating in a report on Monday, February 28th.
In other news, Director R David Hoover purchased 5,000 shares of the company’s stock in a transaction dated Tuesday, March 1st. The shares were acquired at an average cost of $28.66 per share, for a total transaction of $143,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.40% of the stock is owned by corporate insiders.
Shares of ELAN opened at $23.79 on Friday. The company has a market cap of $11.26 billion, a P/E ratio of -24.78, a PEG ratio of 1.12 and a beta of 0.74. The firm’s 50 day moving average price is $26.32 and its 200 day moving average price is $27.97. Elanco Animal Health has a fifty-two week low of $23.25 and a fifty-two week high of $37.49. The company has a quick ratio of 1.16, a current ratio of 1.99 and a debt-to-equity ratio of 0.80.
Elanco Animal Health (NYSE:ELAN – Get Rating) last released its earnings results on Thursday, February 24th. The company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.17 by $0.04. Elanco Animal Health had a negative net margin of 9.91% and a positive return on equity of 6.59%. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.10 billion. During the same period in the prior year, the firm earned $0.12 earnings per share. The business’s quarterly revenue was down 2.3% compared to the same quarter last year. Research analysts forecast that Elanco Animal Health will post 1.2 earnings per share for the current year.
Elanco Animal Health Company Profile (Get Rating)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
- Get a free copy of the StockNews.com research report on Elanco Animal Health (ELAN)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.